Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent HPV Vaccine (Yeast-Derived) in Chinese Women 18-45 Years
CTR20171662Phase 3Completed
- Sponsor
- Sinopharm
- Start
- Jan 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of human papillomavirus 6/11/16/18 vaccine, recombinant in human papillomavirus infection, HPV16 infection (HPV16), human papillomavirus infection type 18 and 4 more (2 arms), sponsored by Sinopharm. Primary endpoints: Vaccine efficacy against 12-month persistent infection with HPV 6/11/16/18 and Vaccine efficacy against CIN2+ cervical lesions associated with HPV 6/11/16/18 infection. Started Jan 2018; status: completed.
02
Drugs
human papillomavirus 6/11/16/18 vaccine, recombinant
03
Conditions
human papillomavirus infectionHPV16 infection (HPV16)human papillomavirus infection type 18cervical intraepithelial neoplasia (CIN)anogenital warts
Beyond the preview
Go deeper on CTR20171662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171662.